nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—KIT—testicular cancer	0.478	1	CbGaD
Regorafenib—UGT1A1—Etoposide—testicular cancer	0.028	0.102	CbGbCtD
Regorafenib—ABCG2—Dactinomycin—testicular cancer	0.0273	0.0993	CbGbCtD
Regorafenib—CYP2B6—Ifosfamide—testicular cancer	0.0226	0.0824	CbGbCtD
Regorafenib—ABCG2—Carboplatin—testicular cancer	0.0183	0.0667	CbGbCtD
Regorafenib—CYP2C8—Ifosfamide—testicular cancer	0.0171	0.0624	CbGbCtD
Regorafenib—ABCG2—Cisplatin—testicular cancer	0.0157	0.057	CbGbCtD
Regorafenib—ABCG2—Etoposide—testicular cancer	0.0154	0.056	CbGbCtD
Regorafenib—CYP2C19—Ifosfamide—testicular cancer	0.0144	0.0524	CbGbCtD
Regorafenib—CYP2C9—Ifosfamide—testicular cancer	0.012	0.0435	CbGbCtD
Regorafenib—CYP2B6—Cisplatin—testicular cancer	0.011	0.0401	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—testicular cancer	0.0105	0.0382	CbGbCtD
Regorafenib—ABCG2—Methotrexate—testicular cancer	0.0102	0.037	CbGbCtD
Regorafenib—ABCB1—Dactinomycin—testicular cancer	0.00983	0.0358	CbGbCtD
Regorafenib—CYP2C8—Etoposide—testicular cancer	0.00819	0.0298	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—testicular cancer	0.00738	0.0269	CbGbCtD
Regorafenib—CYP3A4—Ifosfamide—testicular cancer	0.00695	0.0253	CbGbCtD
Regorafenib—KIT—seminiferous tubule of testis—testicular cancer	0.00663	0.0999	CbGeAlD
Regorafenib—ABCB1—Vinblastine—testicular cancer	0.00616	0.0224	CbGbCtD
Regorafenib—CYP2C9—Cisplatin—testicular cancer	0.00582	0.0212	CbGbCtD
Regorafenib—ABCB1—Cisplatin—testicular cancer	0.00564	0.0206	CbGbCtD
Regorafenib—ABCB1—Etoposide—testicular cancer	0.00555	0.0202	CbGbCtD
Regorafenib—Sorafenib—STK10—testicular cancer	0.00435	0.736	CrCbGaD
Regorafenib—ABCB1—Doxorubicin—testicular cancer	0.00378	0.0138	CbGbCtD
Regorafenib—CYP3A4—Vinblastine—testicular cancer	0.00369	0.0134	CbGbCtD
Regorafenib—ABCB1—Methotrexate—testicular cancer	0.00366	0.0133	CbGbCtD
Regorafenib—CYP3A4—Etoposide—testicular cancer	0.00332	0.0121	CbGbCtD
Regorafenib—CYP3A4—Doxorubicin—testicular cancer	0.00227	0.00825	CbGbCtD
Regorafenib—FRK—gonad—testicular cancer	0.00176	0.0266	CbGeAlD
Regorafenib—Sorafenib—KIT—testicular cancer	0.00156	0.264	CrCbGaD
Regorafenib—NTRK1—testis—testicular cancer	0.00153	0.0231	CbGeAlD
Regorafenib—EPHX2—seminal vesicle—testicular cancer	0.00148	0.0223	CbGeAlD
Regorafenib—FLT4—embryo—testicular cancer	0.00142	0.0214	CbGeAlD
Regorafenib—DDR2—female gonad—testicular cancer	0.00129	0.0194	CbGeAlD
Regorafenib—FRK—testis—testicular cancer	0.00127	0.0192	CbGeAlD
Regorafenib—RET—embryo—testicular cancer	0.00125	0.0189	CbGeAlD
Regorafenib—MAPK11—female gonad—testicular cancer	0.00122	0.0184	CbGeAlD
Regorafenib—FGFR2—embryo—testicular cancer	0.00119	0.018	CbGeAlD
Regorafenib—TEK—embryo—testicular cancer	0.00114	0.0172	CbGeAlD
Regorafenib—DDR2—testis—testicular cancer	0.00114	0.0172	CbGeAlD
Regorafenib—FLT1—embryo—testicular cancer	0.0011	0.0166	CbGeAlD
Regorafenib—EPHA2—seminal vesicle—testicular cancer	0.0011	0.0166	CbGeAlD
Regorafenib—RAF1—embryo—testicular cancer	0.0011	0.0165	CbGeAlD
Regorafenib—MAPK11—testis—testicular cancer	0.00108	0.0163	CbGeAlD
Regorafenib—FLT1—seminal vesicle—testicular cancer	0.00104	0.0156	CbGeAlD
Regorafenib—PDGFRA—embryo—testicular cancer	0.00103	0.0156	CbGeAlD
Regorafenib—RAF1—seminal vesicle—testicular cancer	0.00103	0.0155	CbGeAlD
Regorafenib—KDR—embryo—testicular cancer	0.000933	0.0141	CbGeAlD
Regorafenib—BRAF—female gonad—testicular cancer	0.000909	0.0137	CbGeAlD
Regorafenib—KDR—seminal vesicle—testicular cancer	0.000877	0.0132	CbGeAlD
Regorafenib—EPHX2—female gonad—testicular cancer	0.000868	0.0131	CbGeAlD
Regorafenib—KIT—embryo—testicular cancer	0.000827	0.0125	CbGeAlD
Regorafenib—DDR2—lymph node—testicular cancer	0.000826	0.0125	CbGeAlD
Regorafenib—PDGFRB—embryo—testicular cancer	0.000808	0.0122	CbGeAlD
Regorafenib—BRAF—testis—testicular cancer	0.000806	0.0122	CbGeAlD
Regorafenib—MAPK11—lymph node—testicular cancer	0.000783	0.0118	CbGeAlD
Regorafenib—FLT4—female gonad—testicular cancer	0.000783	0.0118	CbGeAlD
Regorafenib—KIT—seminal vesicle—testicular cancer	0.000777	0.0117	CbGeAlD
Regorafenib—FGFR1—female gonad—testicular cancer	0.000773	0.0116	CbGeAlD
Regorafenib—EPHX2—testis—testicular cancer	0.00077	0.0116	CbGeAlD
Regorafenib—PDGFRB—seminal vesicle—testicular cancer	0.000759	0.0114	CbGeAlD
Regorafenib—FLT1—gonad—testicular cancer	0.000749	0.0113	CbGeAlD
Regorafenib—RAF1—gonad—testicular cancer	0.000745	0.0112	CbGeAlD
Regorafenib—ABL1—embryo—testicular cancer	0.00072	0.0109	CbGeAlD
Regorafenib—PDGFRA—gonad—testicular cancer	0.000702	0.0106	CbGeAlD
Regorafenib—FLT4—testis—testicular cancer	0.000695	0.0105	CbGeAlD
Regorafenib—FGFR1—testis—testicular cancer	0.000685	0.0103	CbGeAlD
Regorafenib—ABL1—seminal vesicle—testicular cancer	0.000676	0.0102	CbGeAlD
Regorafenib—FGFR2—female gonad—testicular cancer	0.000657	0.0099	CbGeAlD
Regorafenib—EPHA2—female gonad—testicular cancer	0.000646	0.00973	CbGeAlD
Regorafenib—TEK—female gonad—testicular cancer	0.00063	0.0095	CbGeAlD
Regorafenib—RET—testis—testicular cancer	0.000613	0.00925	CbGeAlD
Regorafenib—FLT1—female gonad—testicular cancer	0.000609	0.00918	CbGeAlD
Regorafenib—RAF1—female gonad—testicular cancer	0.000605	0.00913	CbGeAlD
Regorafenib—BRAF—lymph node—testicular cancer	0.000584	0.00881	CbGeAlD
Regorafenib—FGFR2—testis—testicular cancer	0.000583	0.00878	CbGeAlD
Regorafenib—EPHA2—testis—testicular cancer	0.000573	0.00863	CbGeAlD
Regorafenib—PDGFRA—female gonad—testicular cancer	0.000571	0.0086	CbGeAlD
Regorafenib—KIT—gonad—testicular cancer	0.000561	0.00846	CbGeAlD
Regorafenib—TEK—testis—testicular cancer	0.000559	0.00842	CbGeAlD
Regorafenib—EPHX2—lymph node—testicular cancer	0.000558	0.00842	CbGeAlD
Regorafenib—PDGFRB—gonad—testicular cancer	0.000548	0.00827	CbGeAlD
Regorafenib—FLT1—testis—testicular cancer	0.00054	0.00814	CbGeAlD
Regorafenib—RAF1—testis—testicular cancer	0.000537	0.0081	CbGeAlD
Regorafenib—KDR—female gonad—testicular cancer	0.000515	0.00776	CbGeAlD
Regorafenib—PDGFRA—testis—testicular cancer	0.000506	0.00763	CbGeAlD
Regorafenib—FLT4—lymph node—testicular cancer	0.000503	0.00759	CbGeAlD
Regorafenib—FGFR1—lymph node—testicular cancer	0.000497	0.00749	CbGeAlD
Regorafenib—ABL1—gonad—testicular cancer	0.000489	0.00737	CbGeAlD
Regorafenib—KDR—testis—testicular cancer	0.000457	0.00688	CbGeAlD
Regorafenib—KIT—female gonad—testicular cancer	0.000456	0.00688	CbGeAlD
Regorafenib—PDGFRB—female gonad—testicular cancer	0.000446	0.00672	CbGeAlD
Regorafenib—RET—lymph node—testicular cancer	0.000444	0.0067	CbGeAlD
Regorafenib—ABCG2—seminal vesicle—testicular cancer	0.000426	0.00643	CbGeAlD
Regorafenib—EPHA2—lymph node—testicular cancer	0.000415	0.00626	CbGeAlD
Regorafenib—TEK—lymph node—testicular cancer	0.000405	0.0061	CbGeAlD
Regorafenib—KIT—testis—testicular cancer	0.000405	0.0061	CbGeAlD
Regorafenib—ABL1—female gonad—testicular cancer	0.000397	0.00599	CbGeAlD
Regorafenib—PDGFRB—testis—testicular cancer	0.000395	0.00596	CbGeAlD
Regorafenib—ABL1—Idarubicin—Epirubicin—testicular cancer	0.000393	0.173	CbGdCrCtD
Regorafenib—ABL1—Doxorubicin—Epirubicin—testicular cancer	0.000393	0.173	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Epirubicin—testicular cancer	0.000393	0.173	CbGdCrCtD
Regorafenib—FLT1—lymph node—testicular cancer	0.000391	0.0059	CbGeAlD
Regorafenib—RAF1—lymph node—testicular cancer	0.000389	0.00587	CbGeAlD
Regorafenib—PDGFRA—lymph node—testicular cancer	0.000367	0.00553	CbGeAlD
Regorafenib—ABL1—Idarubicin—Doxorubicin—testicular cancer	0.000364	0.16	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	0.000364	0.16	CbGdCrCtD
Regorafenib—ABL1—Epirubicin—Doxorubicin—testicular cancer	0.000364	0.16	CbGdCrCtD
Regorafenib—ABL1—testis—testicular cancer	0.000352	0.00531	CbGeAlD
Regorafenib—KDR—lymph node—testicular cancer	0.000331	0.00499	CbGeAlD
Regorafenib—KIT—lymph node—testicular cancer	0.000293	0.00442	CbGeAlD
Regorafenib—PDGFRB—lymph node—testicular cancer	0.000286	0.00432	CbGeAlD
Regorafenib—CYP2B6—gonad—testicular cancer	0.000284	0.00429	CbGeAlD
Regorafenib—ABL1—lymph node—testicular cancer	0.000255	0.00385	CbGeAlD
Regorafenib—ABCG2—female gonad—testicular cancer	0.00025	0.00378	CbGeAlD
Regorafenib—CYP2C8—testis—testicular cancer	0.000228	0.00344	CbGeAlD
Regorafenib—ABCB1—embryo—testicular cancer	0.000224	0.00338	CbGeAlD
Regorafenib—ABCG2—testis—testicular cancer	0.000222	0.00335	CbGeAlD
Regorafenib—ABCB1—seminal vesicle—testicular cancer	0.00021	0.00317	CbGeAlD
Regorafenib—Decreased appetite—Vinblastine—testicular cancer	0.000206	0.00226	CcSEcCtD
Regorafenib—Neoplasm—Methotrexate—testicular cancer	0.000205	0.00225	CcSEcCtD
Regorafenib—Urinary tract disorder—Cisplatin—testicular cancer	0.000205	0.00225	CcSEcCtD
Regorafenib—CYP2B6—testis—testicular cancer	0.000205	0.00309	CbGeAlD
Regorafenib—Leukopenia—Dactinomycin—testicular cancer	0.000205	0.00224	CcSEcCtD
Regorafenib—Abdominal pain—Chlorambucil—testicular cancer	0.000205	0.00224	CcSEcCtD
Regorafenib—Body temperature increased—Chlorambucil—testicular cancer	0.000205	0.00224	CcSEcCtD
Regorafenib—Connective tissue disorder—Cisplatin—testicular cancer	0.000204	0.00223	CcSEcCtD
Regorafenib—Urethral disorder—Cisplatin—testicular cancer	0.000204	0.00223	CcSEcCtD
Regorafenib—Pain—Vinblastine—testicular cancer	0.000203	0.00222	CcSEcCtD
Regorafenib—Hepatobiliary disease—Etoposide—testicular cancer	0.0002	0.0022	CcSEcCtD
Regorafenib—Blood uric acid increased—Doxorubicin—testicular cancer	0.0002	0.00219	CcSEcCtD
Regorafenib—Infection—Bleomycin—testicular cancer	0.000199	0.00218	CcSEcCtD
Regorafenib—Thrombocytopenia—Bleomycin—testicular cancer	0.000196	0.00215	CcSEcCtD
Regorafenib—Gastrointestinal pain—Vinblastine—testicular cancer	0.000194	0.00212	CcSEcCtD
Regorafenib—Anaemia—Ifosfamide—testicular cancer	0.000194	0.00212	CcSEcCtD
Regorafenib—Cardiac disorder—Cisplatin—testicular cancer	0.000193	0.00211	CcSEcCtD
Regorafenib—Neoplasm—Epirubicin—testicular cancer	0.000192	0.0021	CcSEcCtD
Regorafenib—Urinary tract disorder—Etoposide—testicular cancer	0.000188	0.00206	CcSEcCtD
Regorafenib—Leukopenia—Ifosfamide—testicular cancer	0.000188	0.00206	CcSEcCtD
Regorafenib—Abdominal pain—Vinblastine—testicular cancer	0.000187	0.00205	CcSEcCtD
Regorafenib—Mediastinal disorder—Cisplatin—testicular cancer	0.000187	0.00205	CcSEcCtD
Regorafenib—Urethral disorder—Etoposide—testicular cancer	0.000187	0.00204	CcSEcCtD
Regorafenib—Asthenia—Chlorambucil—testicular cancer	0.000186	0.00203	CcSEcCtD
Regorafenib—Infection—Dactinomycin—testicular cancer	0.000186	0.00203	CcSEcCtD
Regorafenib—Alopecia—Cisplatin—testicular cancer	0.000184	0.00201	CcSEcCtD
Regorafenib—Thrombocytopenia—Dactinomycin—testicular cancer	0.000183	0.002	CcSEcCtD
Regorafenib—Hypertension—Ifosfamide—testicular cancer	0.000181	0.00198	CcSEcCtD
Regorafenib—Malnutrition—Cisplatin—testicular cancer	0.000181	0.00198	CcSEcCtD
Regorafenib—Erythema multiforme—Etoposide—testicular cancer	0.00018	0.00197	CcSEcCtD
Regorafenib—Neoplasm—Doxorubicin—testicular cancer	0.000178	0.00195	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000177	0.00194	CcSEcCtD
Regorafenib—Diarrhoea—Chlorambucil—testicular cancer	0.000177	0.00194	CcSEcCtD
Regorafenib—Cardiac disorder—Etoposide—testicular cancer	0.000177	0.00193	CcSEcCtD
Regorafenib—Decreased appetite—Bleomycin—testicular cancer	0.000174	0.00191	CcSEcCtD
Regorafenib—Angiopathy—Etoposide—testicular cancer	0.000173	0.00189	CcSEcCtD
Regorafenib—Mediastinal disorder—Etoposide—testicular cancer	0.000171	0.00188	CcSEcCtD
Regorafenib—Pain—Bleomycin—testicular cancer	0.000171	0.00188	CcSEcCtD
Regorafenib—Asthenia—Vinblastine—testicular cancer	0.00017	0.00186	CcSEcCtD
Regorafenib—Infection—Ifosfamide—testicular cancer	0.00017	0.00186	CcSEcCtD
Regorafenib—Tremor—Cisplatin—testicular cancer	0.000169	0.00185	CcSEcCtD
Regorafenib—Alopecia—Etoposide—testicular cancer	0.000168	0.00184	CcSEcCtD
Regorafenib—Nervous system disorder—Ifosfamide—testicular cancer	0.000168	0.00184	CcSEcCtD
Regorafenib—Thrombocytopenia—Ifosfamide—testicular cancer	0.000168	0.00184	CcSEcCtD
Regorafenib—Anaemia—Cisplatin—testicular cancer	0.000167	0.00183	CcSEcCtD
Regorafenib—Skin disorder—Ifosfamide—testicular cancer	0.000166	0.00182	CcSEcCtD
Regorafenib—Vomiting—Chlorambucil—testicular cancer	0.000165	0.0018	CcSEcCtD
Regorafenib—Decreased appetite—Dactinomycin—testicular cancer	0.000162	0.00178	CcSEcCtD
Regorafenib—Diarrhoea—Vinblastine—testicular cancer	0.000162	0.00178	CcSEcCtD
Regorafenib—Leukopenia—Cisplatin—testicular cancer	0.000162	0.00177	CcSEcCtD
Regorafenib—Fatigue—Dactinomycin—testicular cancer	0.000161	0.00176	CcSEcCtD
Regorafenib—ABCG2—lymph node—testicular cancer	0.000161	0.00243	CbGeAlD
Regorafenib—Pain—Dactinomycin—testicular cancer	0.00016	0.00175	CcSEcCtD
Regorafenib—Body temperature increased—Bleomycin—testicular cancer	0.000158	0.00173	CcSEcCtD
Regorafenib—Hyponatraemia—Epirubicin—testicular cancer	0.000155	0.0017	CcSEcCtD
Regorafenib—Nausea—Chlorambucil—testicular cancer	0.000154	0.00168	CcSEcCtD
Regorafenib—Anaemia—Etoposide—testicular cancer	0.000153	0.00168	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000153	0.00167	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000153	0.00167	CcSEcCtD
Regorafenib—ABCB1—gonad—testicular cancer	0.000152	0.00229	CbGeAlD
Regorafenib—Vomiting—Vinblastine—testicular cancer	0.000151	0.00165	CcSEcCtD
Regorafenib—Decreased appetite—Ifosfamide—testicular cancer	0.000149	0.00163	CcSEcCtD
Regorafenib—Headache—Vinblastine—testicular cancer	0.000149	0.00163	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000148	0.00162	CcSEcCtD
Regorafenib—Leukopenia—Etoposide—testicular cancer	0.000148	0.00162	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000148	0.00162	CcSEcCtD
Regorafenib—Body temperature increased—Dactinomycin—testicular cancer	0.000148	0.00162	CcSEcCtD
Regorafenib—Abdominal pain—Dactinomycin—testicular cancer	0.000148	0.00162	CcSEcCtD
Regorafenib—Fatigue—Ifosfamide—testicular cancer	0.000148	0.00162	CcSEcCtD
Regorafenib—Infection—Cisplatin—testicular cancer	0.000147	0.00161	CcSEcCtD
Regorafenib—Pain—Ifosfamide—testicular cancer	0.000146	0.0016	CcSEcCtD
Regorafenib—Nervous system disorder—Cisplatin—testicular cancer	0.000145	0.00158	CcSEcCtD
Regorafenib—Thrombocytopenia—Cisplatin—testicular cancer	0.000144	0.00158	CcSEcCtD
Regorafenib—Asthenia—Bleomycin—testicular cancer	0.000144	0.00157	CcSEcCtD
Regorafenib—Skin disorder—Cisplatin—testicular cancer	0.000143	0.00157	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—testicular cancer	0.000143	0.00157	CcSEcCtD
Regorafenib—Hypertension—Etoposide—testicular cancer	0.000143	0.00157	CcSEcCtD
Regorafenib—Dry skin—Epirubicin—testicular cancer	0.000141	0.00155	CcSEcCtD
Regorafenib—Nausea—Vinblastine—testicular cancer	0.000141	0.00154	CcSEcCtD
Regorafenib—Hypokalaemia—Epirubicin—testicular cancer	0.00014	0.00154	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00014	0.00153	CcSEcCtD
Regorafenib—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00014	0.00153	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000139	0.00152	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000139	0.00152	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000136	0.00149	CcSEcCtD
Regorafenib—Abdominal pain—Ifosfamide—testicular cancer	0.000135	0.00148	CcSEcCtD
Regorafenib—Body temperature increased—Ifosfamide—testicular cancer	0.000135	0.00148	CcSEcCtD
Regorafenib—Infection—Etoposide—testicular cancer	0.000134	0.00147	CcSEcCtD
Regorafenib—Asthenia—Dactinomycin—testicular cancer	0.000134	0.00147	CcSEcCtD
Regorafenib—Neutropenia—Methotrexate—testicular cancer	0.000133	0.00146	CcSEcCtD
Regorafenib—Thrombocytopenia—Etoposide—testicular cancer	0.000132	0.00145	CcSEcCtD
Regorafenib—Skin disorder—Etoposide—testicular cancer	0.000131	0.00144	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—testicular cancer	0.000131	0.00143	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—testicular cancer	0.00013	0.00142	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000128	0.00141	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000128	0.00141	CcSEcCtD
Regorafenib—Decreased appetite—Cisplatin—testicular cancer	0.000128	0.0014	CcSEcCtD
Regorafenib—Diarrhoea—Dactinomycin—testicular cancer	0.000128	0.0014	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000127	0.00139	CcSEcCtD
Regorafenib—Vomiting—Bleomycin—testicular cancer	0.000127	0.00139	CcSEcCtD
Regorafenib—Infestation NOS—Methotrexate—testicular cancer	0.000127	0.00139	CcSEcCtD
Regorafenib—Infestation—Methotrexate—testicular cancer	0.000127	0.00139	CcSEcCtD
Regorafenib—Rash—Bleomycin—testicular cancer	0.000126	0.00138	CcSEcCtD
Regorafenib—Pain—Cisplatin—testicular cancer	0.000126	0.00138	CcSEcCtD
Regorafenib—Dermatitis—Bleomycin—testicular cancer	0.000126	0.00138	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000126	0.00138	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000126	0.00138	CcSEcCtD
Regorafenib—Neutropenia—Epirubicin—testicular cancer	0.000125	0.00136	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—testicular cancer	0.000124	0.00136	CcSEcCtD
Regorafenib—ABCB1—female gonad—testicular cancer	0.000123	0.00186	CbGeAlD
Regorafenib—Asthenia—Ifosfamide—testicular cancer	0.000123	0.00134	CcSEcCtD
Regorafenib—Weight decreased—Epirubicin—testicular cancer	0.000121	0.00132	CcSEcCtD
Regorafenib—Hepatobiliary disease—Methotrexate—testicular cancer	0.00012	0.00131	CcSEcCtD
Regorafenib—Nausea—Bleomycin—testicular cancer	0.000119	0.0013	CcSEcCtD
Regorafenib—Infestation NOS—Epirubicin—testicular cancer	0.000119	0.0013	CcSEcCtD
Regorafenib—Infestation—Epirubicin—testicular cancer	0.000119	0.0013	CcSEcCtD
Regorafenib—Vomiting—Dactinomycin—testicular cancer	0.000119	0.0013	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000118	0.00129	CcSEcCtD
Regorafenib—Rash—Dactinomycin—testicular cancer	0.000118	0.00129	CcSEcCtD
Regorafenib—Decreased appetite—Etoposide—testicular cancer	0.000118	0.00129	CcSEcCtD
Regorafenib—Diarrhoea—Ifosfamide—testicular cancer	0.000117	0.00128	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Etoposide—testicular cancer	0.000117	0.00128	CcSEcCtD
Regorafenib—Body temperature increased—Cisplatin—testicular cancer	0.000117	0.00128	CcSEcCtD
Regorafenib—Fatigue—Etoposide—testicular cancer	0.000117	0.00128	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—testicular cancer	0.000116	0.00127	CcSEcCtD
Regorafenib—Pain—Etoposide—testicular cancer	0.000116	0.00127	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—testicular cancer	0.000115	0.00126	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—testicular cancer	0.000115	0.00125	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—testicular cancer	0.000114	0.00125	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—testicular cancer	0.000113	0.00123	CcSEcCtD
Regorafenib—Hepatobiliary disease—Epirubicin—testicular cancer	0.000112	0.00123	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—testicular cancer	0.000112	0.00122	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—testicular cancer	0.000112	0.00122	CcSEcCtD
Regorafenib—Nausea—Dactinomycin—testicular cancer	0.000111	0.00121	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etoposide—testicular cancer	0.000111	0.00121	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—testicular cancer	0.00011	0.0012	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—testicular cancer	0.00011	0.0012	CcSEcCtD
Regorafenib—ABCB1—testis—testicular cancer	0.00011	0.00165	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000109	0.00119	CcSEcCtD
Regorafenib—Vomiting—Ifosfamide—testicular cancer	0.000109	0.00119	CcSEcCtD
Regorafenib—Rash—Ifosfamide—testicular cancer	0.000108	0.00118	CcSEcCtD
Regorafenib—Dermatitis—Ifosfamide—testicular cancer	0.000108	0.00118	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—testicular cancer	0.000108	0.00118	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—testicular cancer	0.000107	0.00117	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—testicular cancer	0.000107	0.00117	CcSEcCtD
Regorafenib—Abdominal pain—Etoposide—testicular cancer	0.000107	0.00117	CcSEcCtD
Regorafenib—Body temperature increased—Etoposide—testicular cancer	0.000107	0.00117	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—testicular cancer	0.000107	0.00117	CcSEcCtD
Regorafenib—Asthenia—Cisplatin—testicular cancer	0.000106	0.00116	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—testicular cancer	0.000106	0.00116	CcSEcCtD
Regorafenib—Urinary tract disorder—Epirubicin—testicular cancer	0.000105	0.00115	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—testicular cancer	0.000105	0.00115	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—testicular cancer	0.000105	0.00114	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000104	0.00114	CcSEcCtD
Regorafenib—Angiopathy—Methotrexate—testicular cancer	0.000103	0.00113	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—testicular cancer	0.000103	0.00112	CcSEcCtD
Regorafenib—Nausea—Ifosfamide—testicular cancer	0.000102	0.00111	CcSEcCtD
Regorafenib—Diarrhoea—Cisplatin—testicular cancer	0.000101	0.00111	CcSEcCtD
Regorafenib—Erythema multiforme—Epirubicin—testicular cancer	0.000101	0.0011	CcSEcCtD
Regorafenib—Alopecia—Methotrexate—testicular cancer	0.000101	0.0011	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—testicular cancer	9.92e-05	0.00109	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—testicular cancer	9.92e-05	0.00109	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—testicular cancer	9.9e-05	0.00108	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—testicular cancer	9.87e-05	0.00108	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—testicular cancer	9.75e-05	0.00107	CcSEcCtD
Regorafenib—Asthenia—Etoposide—testicular cancer	9.7e-05	0.00106	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—testicular cancer	9.7e-05	0.00106	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—testicular cancer	9.68e-05	0.00106	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—testicular cancer	9.67e-05	0.00106	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—testicular cancer	9.61e-05	0.00105	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—testicular cancer	9.43e-05	0.00103	CcSEcCtD
Regorafenib—Vomiting—Cisplatin—testicular cancer	9.38e-05	0.00103	CcSEcCtD
Regorafenib—Erythema multiforme—Doxorubicin—testicular cancer	9.33e-05	0.00102	CcSEcCtD
Regorafenib—Rash—Cisplatin—testicular cancer	9.3e-05	0.00102	CcSEcCtD
Regorafenib—Dermatitis—Cisplatin—testicular cancer	9.3e-05	0.00102	CcSEcCtD
Regorafenib—Malnutrition—Epirubicin—testicular cancer	9.29e-05	0.00102	CcSEcCtD
Regorafenib—Diarrhoea—Etoposide—testicular cancer	9.25e-05	0.00101	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—testicular cancer	9.17e-05	0.001	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—testicular cancer	9.16e-05	0.001	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—testicular cancer	8.95e-05	0.00098	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—testicular cancer	8.89e-05	0.000974	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—testicular cancer	8.88e-05	0.000972	CcSEcCtD
Regorafenib—Nausea—Cisplatin—testicular cancer	8.77e-05	0.00096	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—testicular cancer	8.72e-05	0.000955	CcSEcCtD
Regorafenib—Vomiting—Etoposide—testicular cancer	8.6e-05	0.000941	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—testicular cancer	8.59e-05	0.000941	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—testicular cancer	8.58e-05	0.00094	CcSEcCtD
Regorafenib—Rash—Etoposide—testicular cancer	8.52e-05	0.000933	CcSEcCtD
Regorafenib—Dermatitis—Etoposide—testicular cancer	8.52e-05	0.000932	CcSEcCtD
Regorafenib—Headache—Etoposide—testicular cancer	8.47e-05	0.000927	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	8.39e-05	0.000919	CcSEcCtD
Regorafenib—Leukopenia—Epirubicin—testicular cancer	8.31e-05	0.00091	CcSEcCtD
Regorafenib—Infection—Methotrexate—testicular cancer	8.04e-05	0.000881	CcSEcCtD
Regorafenib—Nausea—Etoposide—testicular cancer	8.03e-05	0.000879	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—testicular cancer	8.02e-05	0.000878	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—testicular cancer	7.94e-05	0.00087	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—testicular cancer	7.94e-05	0.000869	CcSEcCtD
Regorafenib—ABCB1—lymph node—testicular cancer	7.94e-05	0.0012	CbGeAlD
Regorafenib—Thrombocytopenia—Methotrexate—testicular cancer	7.93e-05	0.000868	CcSEcCtD
Regorafenib—Skin disorder—Methotrexate—testicular cancer	7.87e-05	0.000861	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	7.85e-05	0.00086	CcSEcCtD
Regorafenib—Dry mouth—Epirubicin—testicular cancer	7.73e-05	0.000847	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—testicular cancer	7.69e-05	0.000842	CcSEcCtD
Regorafenib—Infection—Epirubicin—testicular cancer	7.53e-05	0.000824	CcSEcCtD
Regorafenib—Nervous system disorder—Epirubicin—testicular cancer	7.43e-05	0.000814	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—testicular cancer	7.42e-05	0.000812	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—testicular cancer	7.42e-05	0.000812	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—testicular cancer	7.36e-05	0.000806	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	7.26e-05	0.000795	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—testicular cancer	7.15e-05	0.000783	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—testicular cancer	7.04e-05	0.000771	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—testicular cancer	6.99e-05	0.000765	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—testicular cancer	6.98e-05	0.000764	CcSEcCtD
Regorafenib—Infection—Doxorubicin—testicular cancer	6.97e-05	0.000763	CcSEcCtD
Regorafenib—Pain—Methotrexate—testicular cancer	6.92e-05	0.000758	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—testicular cancer	6.88e-05	0.000753	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—testicular cancer	6.87e-05	0.000752	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—testicular cancer	6.81e-05	0.000746	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—testicular cancer	6.62e-05	0.000725	CcSEcCtD
Regorafenib—Decreased appetite—Epirubicin—testicular cancer	6.59e-05	0.000721	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—testicular cancer	6.54e-05	0.000716	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—testicular cancer	6.53e-05	0.000715	CcSEcCtD
Regorafenib—PDGFRB—Signaling by EGFR in Cancer—KIT—testicular cancer	6.5e-05	0.000797	CbGpPWpGaD
Regorafenib—Pain—Epirubicin—testicular cancer	6.48e-05	0.00071	CcSEcCtD
Regorafenib—PDGFRB—Signaling by PDGF—KIT—testicular cancer	6.47e-05	0.000794	CbGpPWpGaD
Regorafenib—KDR—Extracellular matrix organization—MMP2—testicular cancer	6.44e-05	0.00079	CbGpPWpGaD
Regorafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	6.42e-05	0.000788	CbGpPWpGaD
Regorafenib—RAF1—Signaling by FGFR in disease—FGFR3—testicular cancer	6.42e-05	0.000788	CbGpPWpGaD
Regorafenib—RAF1—DAP12 interactions—FGFR3—testicular cancer	6.42e-05	0.000788	CbGpPWpGaD
Regorafenib—Body temperature increased—Methotrexate—testicular cancer	6.4e-05	0.000701	CcSEcCtD
Regorafenib—Abdominal pain—Methotrexate—testicular cancer	6.4e-05	0.000701	CcSEcCtD
Regorafenib—MAPK11—Signaling by NGF—FGFR3—testicular cancer	6.39e-05	0.000783	CbGpPWpGaD
Regorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	6.38e-05	0.000783	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR—FGFR3—testicular cancer	6.37e-05	0.000781	CbGpPWpGaD
Regorafenib—RAF1—Downstream signal transduction—KIT—testicular cancer	6.36e-05	0.000781	CbGpPWpGaD
Regorafenib—CYP2C19—Biological oxidations—HPGDS—testicular cancer	6.36e-05	0.00078	CbGpPWpGaD
Regorafenib—RAF1—Signaling by FGFR—KIT—testicular cancer	6.33e-05	0.000777	CbGpPWpGaD
Regorafenib—BRAF—Signaling by NGF—FGFR3—testicular cancer	6.33e-05	0.000776	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR in Cancer—FGFR3—testicular cancer	6.31e-05	0.000774	CbGpPWpGaD
Regorafenib—RAF1—Signaling by ERBB2—KIT—testicular cancer	6.3e-05	0.000773	CbGpPWpGaD
Regorafenib—RAF1—Signaling by PDGF—FGFR3—testicular cancer	6.28e-05	0.000771	CbGpPWpGaD
Regorafenib—RAF1—DAP12 signaling—KIT—testicular cancer	6.27e-05	0.000769	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—INSL3—testicular cancer	6.27e-05	0.000769	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—BCL10—testicular cancer	6.25e-05	0.000767	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.24e-05	0.000766	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—INSL3—testicular cancer	6.21e-05	0.000762	CbGpPWpGaD
Regorafenib—Gastrointestinal pain—Epirubicin—testicular cancer	6.2e-05	0.000679	CcSEcCtD
Regorafenib—PDGFRB—B Cell Activation—KIT—testicular cancer	6.12e-05	0.000751	CbGpPWpGaD
Regorafenib—Decreased appetite—Doxorubicin—testicular cancer	6.1e-05	0.000667	CcSEcCtD
Regorafenib—ABL1—Innate Immune System—BCL10—testicular cancer	6.09e-05	0.000747	CbGpPWpGaD
Regorafenib—Gastrointestinal disorder—Doxorubicin—testicular cancer	6.05e-05	0.000663	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—testicular cancer	6.05e-05	0.000662	CcSEcCtD
Regorafenib—PDGFRB—Adaptive Immune System—BCL10—testicular cancer	6e-05	0.000736	CbGpPWpGaD
Regorafenib—Pain—Doxorubicin—testicular cancer	6e-05	0.000657	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—testicular cancer	5.99e-05	0.000656	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—testicular cancer	5.99e-05	0.000656	CcSEcCtD
Regorafenib—RAF1—DAP12 interactions—KIT—testicular cancer	5.9e-05	0.000724	CbGpPWpGaD
Regorafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	5.9e-05	0.000724	CbGpPWpGaD
Regorafenib—RAF1—Signaling by FGFR in disease—KIT—testicular cancer	5.9e-05	0.000724	CbGpPWpGaD
Regorafenib—RAF1—Signaling by NGF—KITLG—testicular cancer	5.89e-05	0.000722	CbGpPWpGaD
Regorafenib—MAPK11—Signaling by NGF—KIT—testicular cancer	5.86e-05	0.000719	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by NGF—FGFR3—testicular cancer	5.86e-05	0.000719	CbGpPWpGaD
Regorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	5.86e-05	0.000719	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR—KIT—testicular cancer	5.85e-05	0.000717	CbGpPWpGaD
Regorafenib—Asthenia—Methotrexate—testicular cancer	5.81e-05	0.000636	CcSEcCtD
Regorafenib—BRAF—Signaling by NGF—KIT—testicular cancer	5.81e-05	0.000712	CbGpPWpGaD
Regorafenib—CYP2C9—Biological oxidations—HPGDS—testicular cancer	5.8e-05	0.000711	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR in Cancer—KIT—testicular cancer	5.79e-05	0.000711	CbGpPWpGaD
Regorafenib—RAF1—Signaling by PDGF—KIT—testicular cancer	5.77e-05	0.000708	CbGpPWpGaD
Regorafenib—KIT—Signaling by NGF—FGFR3—testicular cancer	5.76e-05	0.000706	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—INSL3—testicular cancer	5.75e-05	0.000706	CbGpPWpGaD
Regorafenib—Gastrointestinal pain—Doxorubicin—testicular cancer	5.73e-05	0.000628	CcSEcCtD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	5.71e-05	0.0007	CbGpPWpGaD
Regorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	5.69e-05	0.000698	CbGpPWpGaD
Regorafenib—EPHX2—Metabolism—STK11—testicular cancer	5.68e-05	0.000697	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—INSL3—testicular cancer	5.65e-05	0.000693	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—BCL10—testicular cancer	5.57e-05	0.000683	CbGpPWpGaD
Regorafenib—Body temperature increased—Doxorubicin—testicular cancer	5.54e-05	0.000607	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—testicular cancer	5.54e-05	0.000607	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—testicular cancer	5.54e-05	0.000607	CcSEcCtD
Regorafenib—EPHA2—Developmental Biology—MMP2—testicular cancer	5.54e-05	0.000679	CbGpPWpGaD
Regorafenib—KDR—Axon guidance—MMP2—testicular cancer	5.47e-05	0.000671	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by NGF—FGFR3—testicular cancer	5.46e-05	0.00067	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by NGF—FGFR3—testicular cancer	5.45e-05	0.000669	CbGpPWpGaD
Regorafenib—Asthenia—Epirubicin—testicular cancer	5.44e-05	0.000595	CcSEcCtD
Regorafenib—FGFR2—Signaling by NGF—KIT—testicular cancer	5.38e-05	0.00066	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—INSL3—testicular cancer	5.36e-05	0.000658	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—INSL3—testicular cancer	5.35e-05	0.000656	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—BCL10—testicular cancer	5.35e-05	0.000656	CbGpPWpGaD
Regorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	5.22e-05	0.000641	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.19e-05	0.000637	CbGpPWpGaD
Regorafenib—Diarrhoea—Epirubicin—testicular cancer	5.18e-05	0.000568	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—testicular cancer	5.15e-05	0.000564	CcSEcCtD
Regorafenib—Rash—Methotrexate—testicular cancer	5.11e-05	0.000559	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—testicular cancer	5.1e-05	0.000559	CcSEcCtD
Regorafenib—Headache—Methotrexate—testicular cancer	5.07e-05	0.000555	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—testicular cancer	5.03e-05	0.000551	CcSEcCtD
Regorafenib—FGFR1—Signaling by NGF—KIT—testicular cancer	5.02e-05	0.000615	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by NGF—KIT—testicular cancer	5e-05	0.000614	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by NGF—FGFR3—testicular cancer	4.91e-05	0.000602	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—KITLG—testicular cancer	4.9e-05	0.000601	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—INSL3—testicular cancer	4.82e-05	0.000591	CbGpPWpGaD
Regorafenib—Vomiting—Epirubicin—testicular cancer	4.82e-05	0.000528	CcSEcCtD
Regorafenib—Nausea—Methotrexate—testicular cancer	4.81e-05	0.000527	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—testicular cancer	4.8e-05	0.000525	CcSEcCtD
Regorafenib—Rash—Epirubicin—testicular cancer	4.78e-05	0.000523	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—testicular cancer	4.77e-05	0.000523	CcSEcCtD
Regorafenib—Headache—Epirubicin—testicular cancer	4.75e-05	0.00052	CcSEcCtD
Regorafenib—MAPK11—Immune System—BCL10—testicular cancer	4.73e-05	0.000581	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—H2AFZ—testicular cancer	4.7e-05	0.000576	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—STK11—testicular cancer	4.67e-05	0.000573	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by NGF—KIT—testicular cancer	4.51e-05	0.000553	CbGpPWpGaD
Regorafenib—Nausea—Epirubicin—testicular cancer	4.5e-05	0.000493	CcSEcCtD
Regorafenib—FGFR2—Innate Immune System—KITLG—testicular cancer	4.5e-05	0.000552	CbGpPWpGaD
Regorafenib—Vomiting—Doxorubicin—testicular cancer	4.46e-05	0.000488	CcSEcCtD
Regorafenib—Rash—Doxorubicin—testicular cancer	4.42e-05	0.000484	CcSEcCtD
Regorafenib—KIT—Innate Immune System—KITLG—testicular cancer	4.42e-05	0.000542	CbGpPWpGaD
Regorafenib—Dermatitis—Doxorubicin—testicular cancer	4.42e-05	0.000484	CcSEcCtD
Regorafenib—Headache—Doxorubicin—testicular cancer	4.39e-05	0.000481	CcSEcCtD
Regorafenib—RAF1—Signaling by NGF—FGFR3—testicular cancer	4.38e-05	0.000537	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—BCL10—testicular cancer	4.35e-05	0.000533	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—KITLG—testicular cancer	4.32e-05	0.00053	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—KITLG—testicular cancer	4.32e-05	0.00053	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—INSL3—testicular cancer	4.3e-05	0.000527	CbGpPWpGaD
Regorafenib—KIT—Immune System—BCL10—testicular cancer	4.27e-05	0.000524	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—KITLG—testicular cancer	4.24e-05	0.000521	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—KITLG—testicular cancer	4.19e-05	0.000514	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—KITLG—testicular cancer	4.18e-05	0.000513	CbGpPWpGaD
Regorafenib—Nausea—Doxorubicin—testicular cancer	4.16e-05	0.000456	CcSEcCtD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	4.15e-05	0.000509	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—BCL10—testicular cancer	4.05e-05	0.000497	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—BCL10—testicular cancer	4.04e-05	0.000496	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—KITLG—testicular cancer	4.03e-05	0.000494	CbGpPWpGaD
Regorafenib—FGFR1—Axon guidance—MMP2—testicular cancer	4.02e-05	0.000494	CbGpPWpGaD
Regorafenib—RAF1—Signaling by NGF—KIT—testicular cancer	4.02e-05	0.000493	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—KITLG—testicular cancer	4.02e-05	0.000493	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—MMP2—testicular cancer	3.9e-05	0.000479	CbGpPWpGaD
Regorafenib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	3.82e-05	0.000469	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—KITLG—testicular cancer	3.77e-05	0.000462	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—KITLG—testicular cancer	3.67e-05	0.00045	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—FGFR3—testicular cancer	3.64e-05	0.000447	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—BCL10—testicular cancer	3.64e-05	0.000447	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—KITLG—testicular cancer	3.62e-05	0.000444	CbGpPWpGaD
Regorafenib—ABL1—Immune System—BCL10—testicular cancer	3.55e-05	0.000435	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—MMP2—testicular cancer	3.52e-05	0.000432	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—H2AFZ—testicular cancer	3.51e-05	0.00043	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—STK11—testicular cancer	3.49e-05	0.000428	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—KITLG—testicular cancer	3.36e-05	0.000412	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—MMP2—testicular cancer	3.36e-05	0.000412	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—FGFR3—testicular cancer	3.34e-05	0.00041	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—KIT—testicular cancer	3.34e-05	0.00041	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—FGFR3—testicular cancer	3.28e-05	0.000403	CbGpPWpGaD
Regorafenib—RAF1—Immune System—BCL10—testicular cancer	3.24e-05	0.000398	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—KITLG—testicular cancer	3.23e-05	0.000396	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—KITLG—testicular cancer	3.23e-05	0.000396	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—MMP2—testicular cancer	3.22e-05	0.000395	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—FGFR3—testicular cancer	3.21e-05	0.000394	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—FGFR3—testicular cancer	3.21e-05	0.000394	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—FGFR3—testicular cancer	3.15e-05	0.000387	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—FGFR3—testicular cancer	3.12e-05	0.000382	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—FGFR3—testicular cancer	3.11e-05	0.000381	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—H2AFZ—testicular cancer	3.09e-05	0.000378	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—KIT—testicular cancer	3.07e-05	0.000377	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—FGFR3—testicular cancer	2.99e-05	0.000367	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—FGFR3—testicular cancer	2.99e-05	0.000366	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—KIT—testicular cancer	2.95e-05	0.000362	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—KIT—testicular cancer	2.95e-05	0.000362	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—MMP2—testicular cancer	2.87e-05	0.000352	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—KIT—testicular cancer	2.86e-05	0.000351	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—KITLG—testicular cancer	2.85e-05	0.00035	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—KIT—testicular cancer	2.85e-05	0.00035	CbGpPWpGaD
Regorafenib—BRAF—Disease—H2AFZ—testicular cancer	2.84e-05	0.000348	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—FGFR3—testicular cancer	2.8e-05	0.000344	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—KIT—testicular cancer	2.75e-05	0.000337	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—KIT—testicular cancer	2.74e-05	0.000336	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.73e-05	0.000335	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—FGFR3—testicular cancer	2.73e-05	0.000335	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—FGFR3—testicular cancer	2.69e-05	0.00033	CbGpPWpGaD
Regorafenib—FGFR2—Disease—H2AFZ—testicular cancer	2.63e-05	0.000323	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—KITLG—testicular cancer	2.62e-05	0.000321	CbGpPWpGaD
Regorafenib—BRAF—Disease—KITLG—testicular cancer	2.61e-05	0.00032	CbGpPWpGaD
Regorafenib—KIT—Disease—H2AFZ—testicular cancer	2.58e-05	0.000317	CbGpPWpGaD
Regorafenib—KIT—Immune System—KITLG—testicular cancer	2.57e-05	0.000316	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—KIT—testicular cancer	2.57e-05	0.000315	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—MMP2—testicular cancer	2.51e-05	0.000308	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—KIT—testicular cancer	2.51e-05	0.000307	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—FGFR3—testicular cancer	2.5e-05	0.000306	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—KIT—testicular cancer	2.47e-05	0.000303	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—H2AFZ—testicular cancer	2.47e-05	0.000303	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—STK11—testicular cancer	2.45e-05	0.000301	CbGpPWpGaD
Regorafenib—FGFR1—Disease—H2AFZ—testicular cancer	2.45e-05	0.000301	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—H2AFZ—testicular cancer	2.45e-05	0.0003	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—KITLG—testicular cancer	2.44e-05	0.0003	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.44e-05	0.000299	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—KITLG—testicular cancer	2.44e-05	0.000299	CbGpPWpGaD
Regorafenib—FGFR2—Disease—KITLG—testicular cancer	2.42e-05	0.000297	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—FGFR3—testicular cancer	2.4e-05	0.000294	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—FGFR3—testicular cancer	2.4e-05	0.000294	CbGpPWpGaD
Regorafenib—KIT—Disease—KITLG—testicular cancer	2.38e-05	0.000291	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—H2AFZ—testicular cancer	2.33e-05	0.000286	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—STK11—testicular cancer	2.32e-05	0.000285	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—HPGDS—testicular cancer	2.31e-05	0.000284	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—HPGDS—testicular cancer	2.31e-05	0.000284	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—MMP2—testicular cancer	2.3e-05	0.000282	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—KIT—testicular cancer	2.29e-05	0.000281	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KITLG—testicular cancer	2.27e-05	0.000279	CbGpPWpGaD
Regorafenib—FGFR1—Disease—KITLG—testicular cancer	2.26e-05	0.000277	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—KITLG—testicular cancer	2.25e-05	0.000276	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.23e-05	0.000273	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—H2AFZ—testicular cancer	2.2e-05	0.00027	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—KIT—testicular cancer	2.2e-05	0.00027	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—KIT—testicular cancer	2.2e-05	0.00027	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—KITLG—testicular cancer	2.19e-05	0.000269	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—KITLG—testicular cancer	2.15e-05	0.000263	CbGpPWpGaD
Regorafenib—ABL1—Immune System—KITLG—testicular cancer	2.14e-05	0.000262	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—FGFR3—testicular cancer	2.12e-05	0.00026	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KITLG—testicular cancer	2.03e-05	0.000249	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—H2AFZ—testicular cancer	2.01e-05	0.000246	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—STK11—testicular cancer	1.99e-05	0.000245	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—H2AFZ—testicular cancer	1.99e-05	0.000244	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—STK11—testicular cancer	1.98e-05	0.000242	CbGpPWpGaD
Regorafenib—RAF1—Disease—H2AFZ—testicular cancer	1.96e-05	0.000241	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—HPGDS—testicular cancer	1.96e-05	0.000241	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KITLG—testicular cancer	1.96e-05	0.00024	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—KIT—testicular cancer	1.95e-05	0.000239	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—FGFR3—testicular cancer	1.95e-05	0.000239	CbGpPWpGaD
Regorafenib—BRAF—Disease—FGFR3—testicular cancer	1.94e-05	0.000238	CbGpPWpGaD
Regorafenib—KIT—Immune System—FGFR3—testicular cancer	1.91e-05	0.000235	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KITLG—testicular cancer	1.85e-05	0.000226	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—H2AFZ—testicular cancer	1.84e-05	0.000226	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STK11—testicular cancer	1.83e-05	0.000225	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KITLG—testicular cancer	1.83e-05	0.000224	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—FGFR3—testicular cancer	1.82e-05	0.000223	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—FGFR3—testicular cancer	1.81e-05	0.000222	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—H2AFZ—testicular cancer	1.81e-05	0.000222	CbGpPWpGaD
Regorafenib—RAF1—Disease—KITLG—testicular cancer	1.81e-05	0.000222	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STK11—testicular cancer	1.8e-05	0.000221	CbGpPWpGaD
Regorafenib—FGFR2—Disease—FGFR3—testicular cancer	1.8e-05	0.000221	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—KIT—testicular cancer	1.79e-05	0.000219	CbGpPWpGaD
Regorafenib—BRAF—Disease—KIT—testicular cancer	1.78e-05	0.000219	CbGpPWpGaD
Regorafenib—KIT—Disease—FGFR3—testicular cancer	1.77e-05	0.000217	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—H2AFZ—testicular cancer	1.72e-05	0.000211	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—H2AFZ—testicular cancer	1.71e-05	0.00021	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STK11—testicular cancer	1.71e-05	0.000209	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STK11—testicular cancer	1.7e-05	0.000209	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KITLG—testicular cancer	1.69e-05	0.000208	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—FGFR3—testicular cancer	1.69e-05	0.000207	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—STK11—testicular cancer	1.68e-05	0.000206	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—STK11—testicular cancer	1.68e-05	0.000206	CbGpPWpGaD
Regorafenib—FGFR1—Disease—FGFR3—testicular cancer	1.68e-05	0.000206	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—FGFR3—testicular cancer	1.67e-05	0.000205	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—KIT—testicular cancer	1.67e-05	0.000204	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KITLG—testicular cancer	1.66e-05	0.000204	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—KIT—testicular cancer	1.66e-05	0.000204	CbGpPWpGaD
Regorafenib—FGFR2—Disease—KIT—testicular cancer	1.65e-05	0.000203	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—FGFR3—testicular cancer	1.63e-05	0.0002	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—FGFR3—testicular cancer	1.6e-05	0.000196	CbGpPWpGaD
Regorafenib—ABL1—Immune System—FGFR3—testicular cancer	1.59e-05	0.000195	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KITLG—testicular cancer	1.58e-05	0.000194	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KITLG—testicular cancer	1.58e-05	0.000193	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KIT—testicular cancer	1.55e-05	0.00019	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—H2AFZ—testicular cancer	1.54e-05	0.000189	CbGpPWpGaD
Regorafenib—FGFR1—Disease—KIT—testicular cancer	1.54e-05	0.000189	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—KIT—testicular cancer	1.53e-05	0.000188	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STK11—testicular cancer	1.53e-05	0.000188	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—FGFR3—testicular cancer	1.51e-05	0.000185	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—KIT—testicular cancer	1.5e-05	0.000184	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—KIT—testicular cancer	1.46e-05	0.00018	CbGpPWpGaD
Regorafenib—ABL1—Immune System—KIT—testicular cancer	1.46e-05	0.000179	CbGpPWpGaD
Regorafenib—RAF1—Immune System—FGFR3—testicular cancer	1.45e-05	0.000178	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—HPGDS—testicular cancer	1.44e-05	0.000176	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—STK11—testicular cancer	1.43e-05	0.000175	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KITLG—testicular cancer	1.42e-05	0.000174	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KIT—testicular cancer	1.38e-05	0.00017	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—H2AFZ—testicular cancer	1.37e-05	0.000169	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—FGFR3—testicular cancer	1.37e-05	0.000168	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STK11—testicular cancer	1.37e-05	0.000168	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—FGFR3—testicular cancer	1.36e-05	0.000167	CbGpPWpGaD
Regorafenib—RAF1—Disease—FGFR3—testicular cancer	1.34e-05	0.000165	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KIT—testicular cancer	1.33e-05	0.000164	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KITLG—testicular cancer	1.26e-05	0.000155	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KIT—testicular cancer	1.26e-05	0.000154	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—FGFR3—testicular cancer	1.26e-05	0.000154	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KIT—testicular cancer	1.25e-05	0.000153	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—FGFR3—testicular cancer	1.24e-05	0.000152	CbGpPWpGaD
Regorafenib—RAF1—Disease—KIT—testicular cancer	1.23e-05	0.000151	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—HPGDS—testicular cancer	1.22e-05	0.000149	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—FGFR3—testicular cancer	1.17e-05	0.000144	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—FGFR3—testicular cancer	1.17e-05	0.000144	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KIT—testicular cancer	1.16e-05	0.000142	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—HPGDS—testicular cancer	1.09e-05	0.000133	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KIT—testicular cancer	1.08e-05	0.000132	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KIT—testicular cancer	1.07e-05	0.000132	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—HPGDS—testicular cancer	1.06e-05	0.00013	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—FGFR3—testicular cancer	1.05e-05	0.000129	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—STK11—testicular cancer	1.05e-05	0.000128	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HPGDS—testicular cancer	9.91e-06	0.000122	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KIT—testicular cancer	9.68e-06	0.000119	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—FGFR3—testicular cancer	9.4e-06	0.000115	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—STK11—testicular cancer	8.85e-06	0.000109	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KIT—testicular cancer	8.63e-06	0.000106	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—STK11—testicular cancer	7.9e-06	9.69e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—STK11—testicular cancer	7.71e-06	9.46e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—STK11—testicular cancer	7.2e-06	8.83e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HPGDS—testicular cancer	6.54e-06	8.02e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—STK11—testicular cancer	4.75e-06	5.83e-05	CbGpPWpGaD
